ASCIMINIB
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial PBS-subsidised treatment for patients without T315I mutation
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $6,175.43 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Scemblix | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 13923)
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing treatment for patients without T315I mutation
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $6,132.12 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Scemblix | |||||
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial PBS-subsidised treatment for patients with T315I mutation
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing Treatment for patients with T315I mutation
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 5 | Max qty units: 300 | # of repeats: 5 | DPMQ: $30,225.43 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Scemblix | |||||
Manner of administration:Oral
Restriction
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial PBS-subsidised treatment for patients without T315I mutation
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $6,132.12 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Scemblix | |||||
Manner of administration:Oral
Restriction (Streamlined authority code: 13923)
Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing treatment for patients without T315I mutation
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 60 | # of repeats: 5 | DPMQ: $6,175.43 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Scemblix | |||||